Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Faron Pharmaceuticals

1.98 EUR

-1.10 %

5,528 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
-1.10 %
-17.75 %
-7.57 %
-27.55 %
-22.13 %
-3.98 %
-53.02 %
-37.99 %
-43.16 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
234.52M EUR
Turnover
462.38K EUR
P/E (adj.) (25e)
-8.97
EV/EBIT (adj.) (25e)
-10.32
P/B (25e)
-27.19
EV/S (25e)
58,359.08
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
2.50 EUR
Updated
24.10.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.10.2025

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.3
2026

Annual report '25

30.3
2026

General meeting '26

26.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Faron drew down the second tranche of the convertible bond
Analyst Commentyesterday by
Antti Siltanen

Faron drew down the second tranche of the convertible bond

Of the 35 MEUR convertible bond financing, 25 MEUR has now been drawn.

Faron Pharmaceuticals
Regulatory press release12/11/2025, 8:30 AM

Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement

Faron Pharmaceuticals
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/9/2025, 9:09 PM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Faron presented updated BEXMAB data at the ASH meeting
Analyst Comment12/9/2025, 5:50 AM by
Antti Siltanen

Faron presented updated BEXMAB data at the ASH meeting

Faron announced on Monday the updated results of the BEXMAB trial.

Faron Pharmaceuticals
Press release12/8/2025, 2:42 PM

DNB Carnegie Access: Faron Pharmaceuticals: ASH data shows extended survival benefit

Faron Pharmaceuticals
Press release12/8/2025, 7:00 AM

Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile

Faron Pharmaceuticals
Regulatory press release12/4/2025, 4:00 PM

Faron Pharmaceuticals Ltd: Holding(s) in Company

Faron Pharmaceuticals
Press release12/3/2025, 2:29 PM

DNB Carnegie Access: Faron Pharmaceuticals: Highlights from DNB Carnegie’s Finnish Healthcare seminar

Faron Pharmaceuticals
Regulatory press release12/3/2025, 10:00 AM

Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals
Regulatory press release12/3/2025, 7:00 AM

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Faron Pharmaceuticals
Regulatory press release12/2/2025, 7:00 AM

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals
Regulatory press release12/1/2025, 7:00 AM

Faron Pharmaceuticals Ltd: Appointment of CFO

Faron Pharmaceuticals
Regulatory press release11/27/2025, 7:00 AM

Faron’s Financial Calendar for 2026

Faron Pharmaceuticals
Faron to draw additional 10 MEUR tranche from its convertible bond
Analyst Comment11/25/2025, 9:33 AM by
Antti Luiro

Faron to draw additional 10 MEUR tranche from its convertible bond

No other financing solutions have been announced, and the additional tranche has been part of the company's existing financing reserve, so the release does not come as a particular surprise.

Faron Pharmaceuticals
Regulatory press release11/24/2025, 5:15 PM

INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT

Faron Pharmaceuticals
Press release11/4/2025, 11:39 AM

DNB Carnegie Access: Faron Pharmaceuticals: New oral presentation highlights BEXMAB study interest

Faron Pharmaceuticals
Press release11/4/2025, 7:00 AM

Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy

Faron Pharmaceuticals
Press release11/3/2025, 7:00 AM

Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment

Faron Pharmaceuticals
Regulatory press release10/28/2025, 7:00 AM

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Faron Pharmaceuticals
Faron: The share price drops offers a chance to buy more
Research10/24/2025, 5:36 AM by
Antti Siltanen

Faron: The share price drops offers a chance to buy more

Faron's share price has fallen, which has improved the risk/reward ratio.

Faron Pharmaceuticals
Forum discussions
ascopost.com Amer Zeidan, MBBS, on TP53-Mutated Higher-Risk MDS: Bexmarilimab Plus...
5 hours ago
by poiju
15
December 15 at 10:00 AM (ET).
5 hours ago
15
Clark Kent, can you evaluate this bexmarilimab development from the perspective of how much data competing actors would get for their own development work if all published data were truly detailed, almost perfect? I’m thinking about this from a different educational background. Generally...
4 hours ago
11
If the main owners are not interested in the share issue and the company’s cash situation and outlook are crucial in negotiations with the big players, then practically, the deal should be made while the cash situation is favorable. It’s relatively easy to bake “if the drug does ...
yesterday
by jokuvaan
11
Considering that Faron’s management usually says/implies one thing regarding financing and then does something else, I would argue that Faron does not have any long-term strategy. Or if such a strategy exists on paper, it is interpreted very flexibly.
yesterday
by Sebastian Soderholm
11
I asked because I was wondering if the research method is at all relevant information for an investor. Apparently not? I find several sources according to which TP53m allelic status cannot be reliably obtained with the VAF method, but NGS is needed. “… cases with seemingly monoallelic...
2 hours ago
by RipaRapa
3
My understanding is that trials for other tumors would be financed with funds obtained from MDS partnering. That has likely been Faron’s strategy – or at least one of them.
yesterday
by Mestarihiihtäjä
2
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.